NCT01325688View on ClinicalTrials.gov

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Superficial Basal Cell Carcinoma
Interventions
DRUG

PEP005 (ingenol mebutate) Gel, 0.05%

PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days

DEVICE

Aluminium disk

DEVICE

OpSite(TM) disk

Trial Locations (7)

2217

Southderm Pty Ltd, Kogarah

St George Dermatology, Kogarah

3141

Dermatology Institute of Victoria, South Yarra

4102

Specialist Connect, Woolloongabba

4217

The Skin Centre, Benowa

6008

St John of God Dermatology, Subiaco

6100

Burswood Dermatology, Victoria Park

Sponsors

Lead Sponsor

Peplin
All Listed Sponsors
lead

Peplin

INDUSTRY

NCT01325688 - PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | Biotech Hunter | Biotech Hunter